Advertisement
Letter to the Editors-in-Chief| Volume 224, P1-3, April 2023

Recurrent thrombotic events after disappearance of antiphospholipid autoantibodies: A long-term longitudinal study in patients with antiphospholipid syndrome

  • Thomas Ballul
    Affiliations
    Département de Médecine Interne, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université Paris Cité, Paris, France
    Search for articles by this author
  • Arthur Mageau
    Affiliations
    Département de Médecine Interne, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université Paris Cité, Paris, France
    Search for articles by this author
  • Pascale Roland Nicaise
    Affiliations
    Département de Immunologie, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université Paris Cité, Paris, France
    Search for articles by this author
  • Nadine Ajzenberg
    Affiliations
    Laboratoire d'Hématologie, AP-HP, Hôpital Bichat-Claude Bernard, F-75018 Paris, France

    Université Paris Cité and Université Sorbonne Paris Nord, INSERM1148, LVTS, F-75018 Paris, France
    Search for articles by this author
  • Andrey Strukov
    Affiliations
    Département d'Information Médicale (DIM), Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université Paris Cité, Paris, France
    Search for articles by this author
  • Antoine Dossier
    Affiliations
    Département de Médecine Interne, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université Paris Cité, Paris, France
    Search for articles by this author
  • Diane Rouzaud
    Affiliations
    Département de Médecine Interne, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université Paris Cité, Paris, France
    Search for articles by this author
  • Thomas Papo
    Affiliations
    Département de Médecine Interne, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université Paris Cité, Paris, France
    Search for articles by this author
  • Karim Sacré
    Correspondence
    Corresponding author at: Department of Internal Medicine, Bichat Hospital, APHP, 46 rue Henri Huchard, 75018 Paris, France.
    Affiliations
    Département de Médecine Interne, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université Paris Cité, Paris, France

    Université Paris Cité, Centre de Recherche sur l'Inflammation, INSERM UMR1149, CNRS ERL8252, Faculté de Médecine site Bichat, Laboratoire d'Excellence Inflamex, Paris, France.
    Search for articles by this author
Published:February 09, 2023DOI:https://doi.org/10.1016/j.thromres.2023.02.005
Recurrent thrombotic events after disappearance of antiphospholipid autoantibodies: A long-term longitudinal study in patients with antiphospholipid syndrome
Previous ArticleEculizumab in the management of drug-induced thrombotic microangiopathy: A scoping review of the literature
Next ArticleEffect of therapeutic anticoagulation on gas exchange in mechanically ventilated COVID-19 patients: A secondary analysis of the COVID-HEP trial
      Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the occurrence of thrombosis and/or pregnancy morbidity related to the presence of persistent antiphospholipid autoantibodies (aPL) [
      • Miyakis S.
      • Lockshin M.D.
      • Atsumi T.
      • Branch D.W.
      • Brey R.L.
      • Cervera R.
      • et al.
      International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).
      J. Thromb. Haemost. 2006; 4: 295-306
      ]. The most frequent clinical manifestations of APS are thrombotic events and death may be caused by stroke, myocardial infarction, pulmonary embolism or catastrophic APS [
      • Cervera R.
      • Serrano R.
      • Pons-Estel G.J.
      • Ceberio-Hualde L.
      • Shoenfeld Y.
      • de Ramón E.
      • et al.
      Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients.
      Ann. Rheum. Dis. 2015 Jun; 74: 1011-1018
      ]. APS treatment is based on long term anticoagulation [
      • Tektonidou M.G.
      • Andreoli L.
      • Limper M.
      • Amoura Z.
      • Cervera R.
      • Costedoat-Chalumeau N.
      • et al.
      EULAR recommendations for the management of antiphospholipid syndrome in adults.
      Ann. Rheum. Dis. 2019 Oct; 78: 1296-1304
      ].

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Thrombosis Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Miyakis S.
        • Lockshin M.D.
        • Atsumi T.
        • Branch D.W.
        • Brey R.L.
        • Cervera R.
        • et al.
        International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).
        J. Thromb. Haemost. 2006; 4: 295-306
        View in Article
        • Cervera R.
        • Serrano R.
        • Pons-Estel G.J.
        • Ceberio-Hualde L.
        • Shoenfeld Y.
        • de Ramón E.
        • et al.
        Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients.
        Ann. Rheum. Dis. 2015 Jun; 74: 1011-1018
        View in Article
        • Tektonidou M.G.
        • Andreoli L.
        • Limper M.
        • Amoura Z.
        • Cervera R.
        • Costedoat-Chalumeau N.
        • et al.
        EULAR recommendations for the management of antiphospholipid syndrome in adults.
        Ann. Rheum. Dis. 2019 Oct; 78: 1296-1304
        View in Article
        • Pengo V.
        • Ruffatti A.
        • Legnani C.
        • Testa S.
        • Fierro T.
        • Marongiu F.
        • et al.
        Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study.
        Blood. 2011 Oct 27; 118: 4714-4718
        View in Article
        • Radin M.
        • Schreiber K.
        • Sciascia S.
        • Roccatello D.
        • Cecchi I.
        • Aguirre Zamorano M.Á.
        • et al.
        Prevalence of antiphospholipid antibodies negativisation in patients with antiphospholipid syndrome: a long-term follow-up multicentre study.
        Thromb. Haemost. 2019 Dec; 119: 1920-1926
        View in Article
        • Devreese K.M.J.
        • de Groot P.G.
        • de Laat B.
        • Erkan D.
        • Favaloro E.J.
        • Mackie I.
        • et al.
        Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation.
        J. Thromb. Haemost. 2020 Nov; 18: 2828-2839
        View in Article
        • Aringer M.
        • Costenbader K.
        • Daikh D.
        • Brinks R.
        • Mosca M.
        • Ramsey-Goldman R.
        • et al.
        2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus.
        Ann. Rheum. Dis. 2019 Sep; 78: 1151-1159
        View in Article
        • Yelnik C.M.
        • Urbanski G.
        • Drumez E.
        • Caron C.
        • Maillard H.
        • Morell-Dubois S.
        • et al.
        Anticoagulation withdrawal in antiphospholipid syndrome: a retrospective matched-control study.
        Lupus. 2018 Mar; 27: 357-364
        View in Article
        • Comarmond C.
        • Jego P.
        • Veyssier-Belot C.
        • Marie I.
        • Mekinian A.
        • Elmaleh-Sachs A.
        • et al.
        Cessation of oral anticoagulants in antiphospholipid syndrome.
        Lupus. 2017 Oct; 26: 1291-1296
        View in Article
        • Coloma Bazán E.
        • Donate López C.
        • Moreno Lozano P.
        • Cervera R.
        • Espinosa G.
        Discontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negative.
        Immunol. Res. 2013 Jul; 56: 358-361
        View in Article

      Article info

      Publication history

      Published online: February 09, 2023
      Accepted: February 4, 2023
      Received in revised form: January 30, 2023
      Received: December 12, 2022

      Identification

      DOI: https://doi.org/10.1016/j.thromres.2023.02.005

      Copyright

      © 2023 Elsevier Ltd. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX